Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Active not recruiting 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Breast Neoplasms 672Carcinoma, Non-Small-Cell Lung 461Prostatic Neoplasms 391Neoplasms 383Lung Neoplasms 265Multiple Myeloma 249Colorectal Neoplasms 235Neoplasm Metastasis 216Melanoma 203Ovarian Neoplasms 166Leukemia, Myeloid, Acute 165Pancreatic Neoplasms 156Carcinoma, Renal Cell 142Squamous Cell Carcinoma of Head and Neck 141Lymphoma 137Brain Neoplasms 133Leukemia, Lymphocytic, Chronic, B-Cell 126Glioblastoma 126Recurrence 125Lymphoma, Non-Hodgkin 124Carcinoma, Hepatocellular 119Head and Neck Neoplasms 114Urinary Bladder Neoplasms 111Triple Negative Breast Neoplasms 110Stomach Neoplasms 109Precursor Cell Lymphoblastic Leukemia-Lymphoma 105Uterine Cervical Neoplasms 102Hematologic Neoplasms 99Lymphoma, Follicular 96Sarcoma 95

Interventions

trametinib 1ribociclib 1nazartinib 1naporafenib 1capmatinib 1Gefitinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Active not recruiting × EGFR-mutant Non-small Cell Lung Cancer × 1 year × Clear all
NCT03333343 2026-01-16

Study of EGF816 in Combination With Selected Targeted Agents in EGFR-mutant NSCLC

Novartis

Phase 1 Active not recruiting
105 enrolled
Thoracic

EGFR-mutant Non-small Cell Lung Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡